scholarly journals Semigenerated Carnot algebras and applications to sub-Riemannian perimeter

Author(s):  
Enrico Le Donne ◽  
Terhi Moisala

AbstractThis paper contributes to the study of sets of finite intrinsic perimeter in Carnot groups. Our intent is to characterize in which groups the only sets with constant intrinsic normal are the vertical half-spaces. Our viewpoint is algebraic: such a phenomenon happens if and only if the semigroup generated by each horizontal half-space is a vertical half-space. We call semigenerated those Carnot groups with this property. For Carnot groups of nilpotency step 3 we provide a complete characterization of semigeneration in terms of whether such groups do not have any Engel-type quotients. Engel-type groups, which are introduced here, are the minimal (in terms of quotients) counterexamples. In addition, we give some sufficient criteria for semigeneration of Carnot groups of arbitrary step. For doing this, we define a new class of Carnot groups, which we call type $$(\Diamond )$$ ( ◊ ) and which generalizes the previous notion of type $$(\star )$$ ( ⋆ ) defined by M. Marchi. As an application, we get that in type $$ (\Diamond ) $$ ( ◊ ) groups and in step 3 groups that do not have any Engel-type algebra as a quotient, one achieves a strong rectifiability result for sets of finite perimeter in the sense of Franchi, Serapioni, and Serra-Cassano.

1982 ◽  
Vol 10 (1) ◽  
pp. 37-54 ◽  
Author(s):  
M. Kumar ◽  
C. W. Bert

Abstract Unidirectional cord-rubber specimens in the form of tensile coupons and sandwich beams were used. Using specimens with the cords oriented at 0°, 45°, and 90° to the loading direction and appropriate data reduction, we were able to obtain complete characterization for the in-plane stress-strain response of single-ply, unidirectional cord-rubber composites. All strains were measured by means of liquid mercury strain gages, for which the nonlinear strain response characteristic was obtained by calibration. Stress-strain data were obtained for the cases of both cord tension and cord compression. Materials investigated were aramid-rubber, polyester-rubber, and steel-rubber.


Author(s):  
G. Meneghesso ◽  
E. Zanoni ◽  
P. Colombo ◽  
M. Brambilla ◽  
R. Annunziata ◽  
...  

Abstract In this work, we present new results concerning electrostatic discharge (ESD) robustness of 0.6 μm CMOS structures. Devices have been tested according to both HBM and socketed CDM (sCDM) ESD test procedures. Test structures have been submitted to a complete characterization consisting in: 1) measurement of the tum-on time of the protection structures submitted to pulses with very fast rise times; 2) ESD stress test with the HBM and sCDM models; 3) failure analysis based on emission microscopy (EMMI) and Scanning Electron Microscopy (SEM).


2020 ◽  
Vol 20 (7) ◽  
pp. 490-500 ◽  
Author(s):  
Justin S. Becker ◽  
Amir T. Fathi

The genomic characterization of acute myeloid leukemia (AML) by DNA sequencing has illuminated subclasses of the disease, with distinct driver mutations, that might be responsive to targeted therapies. Approximately 15-23% of AML genomes harbor mutations in one of two isoforms of isocitrate dehydrogenase (IDH1 or IDH2). These enzymes are constitutive mediators of basic cellular metabolism, but their mutated forms in cancer synthesize an abnormal metabolite, 2- hydroxyglutarate, that in turn acts as a competitive inhibitor of multiple gene regulatory enzymes. As a result, leukemic IDH mutations cause changes in genome structure and gene activity, culminating in an arrest of normal myeloid differentiation. These discoveries have motivated the development of a new class of selective small molecules with the ability to inhibit the mutant IDH enzymes while sparing normal cellular metabolism. These agents have shown promising anti-leukemic activity in animal models and early clinical trials, and are now entering Phase 3 study. This review will focus on the growing preclinical and clinical data evaluating IDH inhibitors for the treatment of IDH-mutated AML. These data suggest that inducing cellular differentiation is central to the mechanism of clinical efficacy for IDH inhibitors, while also mediating toxicity for patients who experience IDH Differentiation Syndrome. Ongoing trials are studying the efficacy of IDH inhibitors in combination with other AML therapies, both to evaluate potential synergistic combinations as well as to identify the appropriate place for IDH inhibitors within existing standard-of-care regimens.


Sign in / Sign up

Export Citation Format

Share Document